Erin Pennock Foff
CIK: 0002021233
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
MapLight Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (27 total)
- Oct 15, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct15.4K shares at avg. $8.08$124K - Aug 17, 2026MPLT
MapLight Therapeutics, Inc.
Award(A)Direct13.4K shares- - Jul 17, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct3.7K shares at avg. $37.90$139K - Jul 16, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct9.2K shares at avg. $36.46$334K - Jul 16, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct5.9K shares at avg. $37.26$219K - Jul 16, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct19 shares at avg. $37.96$721.24 - Jul 15, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct7.8K shares at avg. $37.04$291K - Jul 15, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct9K shares at avg. $36.99$332K - Jul 15, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct18 shares at avg. $37.54$675.72 - Jul 15, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct7.2K shares at avg. $36.16$259K - Jul 15, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct4.5K shares at avg. $36.00$161K - May 7, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct117 shares at avg. $29.10$3K - May 7, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct4.3K shares at avg. $28.52$123K - May 6, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct8.2K shares at avg. $28.04$229K - May 6, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct15.9K shares at avg. $29.13$463K - May 5, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct9.6K shares at avg. $28.12$271K - May 5, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct931 shares at avg. $29.00$27K - May 4, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct5.5K shares at avg. $28.37$155K - May 4, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct312 shares at avg. $29.56$9K - May 4, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct700 shares at avg. $30.08$21K - May 4, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct9.2K shares at avg. $27.50$252K - Apr 16, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct881 shares at avg. $27.49$24K - Apr 16, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct288 shares at avg. $27.01$8K - Apr 15, 2026MPLT
MapLight Therapeutics, Inc.
Sale(S)Direct2K shares at avg. $26.84$55K - Feb 5, 2026MPLT
MapLight Therapeutics, Inc.
Award(A)Direct13.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 15, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 15,355 | $8.08 | $124,068 | Direct |
| Aug 17, 2026 | MPLT MapLight Therapeutics, Inc. | Award(A) | 13,360 | - | $0 | Direct |
| Jul 17, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 3,656 | $37.90 | $138,562 | Direct |
| Jul 16, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 9,163 | $36.46 | $334,083 | Direct |
| Jul 16, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 5,865 | $37.26 | $218,530 | Direct |
| Jul 16, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 19 | $37.96 | $721 | Direct |
| Jul 15, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 7,845 | $37.04 | $290,579 | Direct |
| Jul 15, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 8,972 | $36.99 | $331,874 | Direct |
| Jul 15, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 18 | $37.54 | $676 | Direct |
| Jul 15, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 7,155 | $36.16 | $258,725 | Direct |
| Jul 15, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 4,465 | $36.00 | $160,740 | Direct |
| May 7, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 117 | $29.10 | $3,405 | Direct |
| May 7, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 4,321 | $28.52 | $123,235 | Direct |
| May 6, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 8,152 | $28.04 | $228,582 | Direct |
| May 6, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 15,900 | $29.13 | $463,167 | Direct |
| May 5, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 9,645 | $28.12 | $271,217 | Direct |
| May 5, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 931 | $29.00 | $26,999 | Direct |
| May 4, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 5,460 | $28.37 | $154,900 | Direct |
| May 4, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 312 | $29.56 | $9,223 | Direct |
| May 4, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 700 | $30.08 | $21,056 | Direct |
| May 4, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 9,180 | $27.50 | $252,450 | Direct |
| Apr 16, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 881 | $27.49 | $24,219 | Direct |
| Apr 16, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 288 | $27.01 | $7,779 | Direct |
| Apr 15, 2026 | MPLT MapLight Therapeutics, Inc. | Sale(S) | 2,044 | $26.84 | $54,861 | Direct |
| Feb 5, 2026 | MPLT MapLight Therapeutics, Inc. | Award(A) | 13,360 | - | $0 | Direct |
1-25 of 27 transactions
About Foff Erin Pennock
Foff Erin Pennock (SEC CIK 0002021233) files insider reports with the SEC as Chief Medical Officer of MapLight Therapeutics, Inc. (MPLT).
Signal8 holds 10 ownership filings by Foff Erin Pennock (1 Form 3, 9 Form 4), filed between Oct 27, 2025 and Oct 16, 2026. Those filings report 27 transactions, from Oct 27, 2025 to Oct 15, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Foff Erin Pennock's filings is in REDWOOD CITY, CA.
Recent filings by Foff Erin Pennock
- Oct 15, 2026: Open-market sale of MPLT shares (Form 4, code S).
- Aug 17, 2026: Grant or award of MPLT shares (Form 4, code A).
- Jul 17, 2026: Open-market sale of MPLT shares (Form 4, code S).
- Jul 16, 2026: Open-market sales of MPLT shares (3 lines, Form 4, code S).
- Jul 15, 2026: Open-market sales of MPLT shares (5 lines, Form 4, code S).
Other insiders filing for MapLight Therapeutics, Inc. (MPLT)
- Kreitzer Anatol, Chief Discovery Officer
- GILLIS JONATHAN, CAO and Interim CFO
- Lillie James Woodruff, Chief Scientific Officer
- Hanson Kristopher, General Counsel
- Kroeger Christopher A., Chief Executive Officer
- Cox Troy, Director